Eli Lilly shares are cratering after the FDA rejected a $1 billion arthritis drug on safety concerns
April 17, 2017 at 07:38 AM EDT
Lilly said the FDA needed additional data to "characterize safety concerns across treatment arms" and to determine "the most appropriate doses."
